$KZR
Kezar Life Sciences, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024096213 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.706M
YoY Change -35.09%
% of Gross Profit
Research & Development $16.24M $16.30M
YoY Change -31.58% -22.39%
% of Gross Profit
Depreciation & Amortization $300.0K $300.0K
YoY Change 0.0% 50.0%
% of Gross Profit
Operating Expenses $21.95M $23.38M
YoY Change -32.52% -12.7%
Operating Profit -$21.95M -$23.38M
YoY Change -14.02% -12.7%
Interest Expense $403.0K $401.0K
YoY Change 1.77% 4.16%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$20.31M
YoY Change -12.06%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$20.31M -$21.55M
YoY Change -12.08% -11.36%
Net Earnings / Revenue
Basic Earnings Per Share -$2.78 -$0.30
Diluted Earnings Per Share -$2.78 -$0.30
COMMON SHARES
Basic Shares Outstanding 72.96M 72.80M
Diluted Shares Outstanding 7.296M 72.85M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.4M $164.2M
YoY Change -31.99% -30.6%
Cash & Equivalents $34.86M $28.28M
Short-Term Investments $113.5M $135.9M
Other Short-Term Assets $6.902M $1.749M
YoY Change 638.18% 87.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $156.4M $167.6M
YoY Change -32.16% -31.16%
LONG-TERM ASSETS
Property, Plant & Equipment $3.149M $3.391M
YoY Change -28.48% -27.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.415M $6.522M
YoY Change -61.88% -0.61%
Total Long-Term Assets $7.707M $12.30M
YoY Change -59.03% -38.09%
TOTAL ASSETS
Total Short-Term Assets $156.4M $167.6M
Total Long-Term Assets $7.707M $12.30M
Total Assets $164.1M $179.9M
YoY Change -34.19% -31.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.461M $2.263M
YoY Change 10.93% -9.19%
Accrued Expenses $9.664M $9.363M
YoY Change -9.32% 10.63%
Deferred Revenue
YoY Change
Short-Term Debt $3.913M $2.609M
YoY Change
Long-Term Debt Due $3.913M $2.609M
YoY Change
Total Short-Term Liabilities $20.43M $17.50M
YoY Change 22.53% 27.36%
LONG-TERM LIABILITIES
Long-Term Debt $6.349M $7.589M
YoY Change -36.57% -23.74%
Other Long-Term Liabilities $3.259M $4.152M
YoY Change -51.36% -43.99%
Total Long-Term Liabilities $6.349M $7.589M
YoY Change -36.57% -23.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.43M $17.50M
Total Long-Term Liabilities $6.349M $7.589M
Total Liabilities $30.04M $29.24M
YoY Change -9.89% -6.0%
SHAREHOLDERS EQUITY
Retained Earnings -$414.3M -$394.0M
YoY Change 30.08% 33.38%
Common Stock $548.2M $545.0M
YoY Change 2.44% 3.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $134.0M $150.7M
YoY Change
Total Liabilities & Shareholders Equity $164.1M $179.9M
YoY Change -34.19% -31.69%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$20.31M -$21.55M
YoY Change -12.08% -11.36%
Depreciation, Depletion And Amortization $300.0K $300.0K
YoY Change 0.0% 50.0%
Cash From Operating Activities -$17.49M -$17.03M
YoY Change -13.44% -21.15%
INVESTING ACTIVITIES
Capital Expenditures $18.00K $0.00
YoY Change -87.14% -100.0%
Acquisitions
YoY Change
Other Investing Activities $24.08M $12.22M
YoY Change 28.69% -16.21%
Cash From Investing Activities $24.06M $12.22M
YoY Change 29.49% -7.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 56.00K
YoY Change -100.0% -85.34%
NET CHANGE
Cash From Operating Activities -17.49M -17.03M
Cash From Investing Activities 24.06M 12.22M
Cash From Financing Activities 0.000 56.00K
Net Change In Cash 6.566M -4.759M
YoY Change -512.96% -40.62%
FREE CASH FLOW
Cash From Operating Activities -$17.49M -$17.03M
Capital Expenditures $18.00K $0.00
Free Cash Flow -$17.51M -$17.03M
YoY Change -13.95% -25.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001645666
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38542
dei Entity Registrant Name
EntityRegistrantName
Kezar Life Sciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3366145
dei Entity Address Address Line1
EntityAddressAddressLine1
4000 Shoreline Court
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
822-5600
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
KZR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
72962220
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28276000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35493000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
135906000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
165879000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3435000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5578000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
167617000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
206950000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3391000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3912000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2391000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4778000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6522000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5595000
CY2024Q2 us-gaap Assets
Assets
179921000
CY2023Q4 us-gaap Assets
Assets
221235000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2263000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8251000
CY2024Q2 kzr Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
9363000
CY2023Q4 kzr Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
6481000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3260000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3012000
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2609000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17495000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17744000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4152000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5852000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7589000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10069000
CY2024Q2 us-gaap Liabilities
Liabilities
29236000
CY2023Q4 us-gaap Liabilities
Liabilities
33665000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72887538
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72887538
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72779077
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72779077
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
73000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
73000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
544965000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
538390000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-385000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-130000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-393968000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-350763000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
150685000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
187570000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
179921000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
221235000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16298000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20999000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33470000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39317000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5603000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5785000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12142000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11991000
CY2024Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1482000
CY2023Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1482000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
23383000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
26784000
us-gaap Operating Expenses
OperatingExpenses
47094000
us-gaap Operating Expenses
OperatingExpenses
51308000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23383000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26784000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47094000
us-gaap Operating Income Loss
OperatingIncomeLoss
-51308000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2237000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2861000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4690000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5556000
CY2024Q2 us-gaap Interest Expense
InterestExpense
401000
CY2023Q2 us-gaap Interest Expense
InterestExpense
385000
us-gaap Interest Expense
InterestExpense
801000
us-gaap Interest Expense
InterestExpense
755000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21547000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24308000
us-gaap Net Income Loss
NetIncomeLoss
-43205000
us-gaap Net Income Loss
NetIncomeLoss
-46507000
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72845869
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72845869
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72461850
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72461850
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72822890
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72822890
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72395410
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72395410
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21547000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24308000
us-gaap Net Income Loss
NetIncomeLoss
-43205000
us-gaap Net Income Loss
NetIncomeLoss
-46507000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
14000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-302000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-240000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
110000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-30000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-307000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-255000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
93000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21577000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24615000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43460000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46414000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
187570000
CY2024Q1 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3434000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-225000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-21658000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
169121000
CY2024Q2 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
56000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3085000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-30000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21547000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
150685000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
269872000
CY2023Q1 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
154000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4263000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
400000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22199000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
252490000
CY2023Q2 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
382000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4020000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-307000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24308000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
232277000
us-gaap Profit Loss
ProfitLoss
-43205000
us-gaap Profit Loss
ProfitLoss
-46507000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
521000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
508000
us-gaap Share Based Compensation
ShareBasedCompensation
6519000
us-gaap Share Based Compensation
ShareBasedCompensation
8283000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2902000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3532000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
129000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
118000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
1549000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2143000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2246000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
927000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
5888000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3106000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2453000
kzr Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
614000
kzr Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
141000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39893000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42460000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1673000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
52126000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
95233000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
84750000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
126500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
32624000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29594000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
56000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
536000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
536000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-4000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-17000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7217000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12347000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35493000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40456000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28276000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28109000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
117000
kzr Par Value Of Common Stock Upon Cashless Exercise Of Prefunded Warrants
ParValueOfCommonStockUponCashlessExerciseOfPrefundedWarrants
0
kzr Par Value Of Common Stock Upon Cashless Exercise Of Prefunded Warrants
ParValueOfCommonStockUponCashlessExerciseOfPrefundedWarrants
4000
us-gaap Interest Paid Net
InterestPaidNet
672000
us-gaap Interest Paid Net
InterestPaidNet
637000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such judgments, estimates and assumptions include the valuation of marketable securities, impairment of long-lived assets, determining the fair-value of stock-based compensation, and evaluating the progress to completion of external research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its judgments, estimates and assumptions or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements.</span></p>
CY2023 kzr Interest Rate Of Sublease Income Per Year
InterestRateOfSubleaseIncomePerYear
0.035
CY2023 kzr Discount Rate Of Cash Flow
DiscountRateOfCashFlow
0.133
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
1500000
kzr Estimated Future Sublease Income
EstimatedFutureSubleaseIncome
0
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
110851000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
128000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
76102000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
103000
CY2024Q2 kzr Debt Securities Avalilable For Sale Credit Related Losses
DebtSecuritiesAvalilableForSaleCreditRelatedLosses
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
164188000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
164064000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
164188000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
164064000
CY2024Q2 kzr Receivable From Collaboration
ReceivableFromCollaboration
1312000
CY2023Q4 kzr Receivable From Collaboration
ReceivableFromCollaboration
1596000
CY2024Q2 kzr Prepaid Advance For Clinical Related Costs Current
PrepaidAdvanceForClinicalRelatedCostsCurrent
773000
CY2023Q4 kzr Prepaid Advance For Clinical Related Costs Current
PrepaidAdvanceForClinicalRelatedCostsCurrent
1818000
CY2024Q2 kzr Prepaid License Dues And Subscription
PrepaidLicenseDuesAndSubscription
662000
CY2023Q4 kzr Prepaid License Dues And Subscription
PrepaidLicenseDuesAndSubscription
506000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
104000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
712000
CY2024Q2 us-gaap Interest Receivable
InterestReceivable
374000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
695000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
210000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
251000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3435000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5578000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9332000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9332000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5941000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5420000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3391000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3912000
CY2024Q2 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
500000
CY2023Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
500000
CY2024Q2 kzr Other Assets Advance For Clinical Related Costs Non Current
OtherAssetsAdvanceForClinicalRelatedCostsNonCurrent
4670000
CY2023Q4 kzr Other Assets Advance For Clinical Related Costs Non Current
OtherAssetsAdvanceForClinicalRelatedCostsNonCurrent
4787000
CY2024Q2 kzr Other Unbilled Receivable Non Current
OtherUnbilledReceivableNonCurrent
1099000
CY2023Q4 kzr Other Unbilled Receivable Non Current
OtherUnbilledReceivableNonCurrent
0
CY2024Q2 kzr Other Assets Deposits For Operating Lease
OtherAssetsDepositsForOperatingLease
674000
CY2023Q4 kzr Other Assets Deposits For Operating Lease
OtherAssetsDepositsForOperatingLease
674000
CY2024Q2 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
79000
CY2023Q4 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
134000
CY2024Q2 us-gaap Other Assets
OtherAssets
6522000
CY2023Q4 us-gaap Other Assets
OtherAssets
5595000
CY2024Q2 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
5909000
CY2023Q4 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
1801000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1802000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3708000
CY2024Q2 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
1532000
CY2023Q4 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
756000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
55000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
110000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
65000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9363000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6481000
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2700000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
1500000
kzr Estimated Future Sublease Income
EstimatedFutureSubleaseIncome
0
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
741000
us-gaap Operating Lease Payments
OperatingLeasePayments
1452000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
655000
us-gaap Operating Lease Cost
OperatingLeaseCost
1322000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
467000
us-gaap Variable Lease Cost
VariableLeaseCost
916000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3957000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4095000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
347000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8399000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
987000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
7412000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3260000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4152000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
7412000
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
189000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
243000
CY2024Q2 kzr Cumulative Accretion Of Final Fee
CumulativeAccretionOfFinalFee
387000
CY2023Q4 kzr Cumulative Accretion Of Final Fee
CumulativeAccretionOfFinalFee
312000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
10198000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
10069000
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2609000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7589000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10069000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
10198000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
10069000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5217000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4783000
CY2024Q2 kzr Long Term Debt Principal Amount
LongTermDebtPrincipalAmount
10000000
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P20Y
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
kzr Unvested Option Shares Cancelled Due To Termination
UnvestedOptionSharesCancelledDueToTermination
600000
CY2024Q2 kzr Share Based Compensation Expense Plan Modification Unamortized Incremental Compensation Cost Of Unvested Option Shares
ShareBasedCompensationExpensePlanModificationUnamortizedIncrementalCompensationCostOfUnvestedOptionShares
1100000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13110717
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.60
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
118000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3541000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.9
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1395135
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.84
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15256582
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.18
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2024Q2 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
8334868
CY2024Q2 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
2.58
kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
P5Y8M12D
CY2024Q2 kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3085000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4020000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6519000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8283000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.868
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.877
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.88
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.883
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.868
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.879
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.878
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.883
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.043
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.046
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.046
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.043
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
1400000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21547000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24308000
us-gaap Net Income Loss
NetIncomeLoss
-43205000
us-gaap Net Income Loss
NetIncomeLoss
-46507000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72845869
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72461850
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72822890
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72395410
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15441998
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15441998
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13395616
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13395616
CY2023 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
6200000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
1500000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
200000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
1400000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023 us-gaap Restructuring Charges
RestructuringCharges
6187000
CY2023 us-gaap Payments For Restructuring
PaymentsForRestructuring
1858000
CY2023 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
2908000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
1421000
CY2024Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
775000
CY2024Q1 us-gaap Restructuring Reserve
RestructuringReserve
646000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
1482000
CY2024Q2 us-gaap Payments For Restructuring
PaymentsForRestructuring
344000
CY2024Q2 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
1549000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
235000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 kzr Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q2 kzr Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0000950170-24-096213-index-headers.html Edgar Link pending
0000950170-24-096213-index.html Edgar Link pending
0000950170-24-096213.txt Edgar Link pending
0000950170-24-096213-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img40159629_0.jpg Edgar Link pending
kzr-20240630.htm Edgar Link pending
kzr-20240630.xsd Edgar Link pending
kzr-ex10_1.htm Edgar Link pending
kzr-ex31_1.htm Edgar Link pending
kzr-ex31_2.htm Edgar Link pending
kzr-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kzr-20240630_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending